Alvion Pharmaceuticals and V-Ensure announce positive results on Pilot studies for Mirabegron Prolonged Release 25mg, 50mg f.c. tablets

The product is a generic medicine equivalent to MYRBETRIQ™ discovered by Astellas indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency, is now available for its partners across the world.

DCPs with Netherlands as RMS have been already scheduled for Q4 2023 targeting to offer the first generic Marketing Authorizations in Europe.

Alvion along with V-Ensure, its co-development partner and manufacturer consider they are the only companies to offer a non infringing formulation of Mirabegron PR in Europe, backed by formulation patents, aiming to penetrate significant market share in Europe, MENA, Australia, Africa, Canada and other territories following its patent expiry. 

John Bouros, CEO of Alvion, said: “We are thrilled to offer such a complex development with a number of studies performed to the healthcare community. High value proprietaries such as Mirabegron PR is our focus on new developments, and we are committed to successfully deliver at Day 1 to our big pharma partners across the world. Specializing in such type of high technology products is a priority for Alvion, targeting long term strategic collaborations offering competitive advantages in the supply chain. 

About Alvion

Alvion Pharmaceuticals P.C. (Alvion), Athens Greece and Galway Ireland is an international pharmaceutical company focusing on the development of added value and generic medicines in various therapeutic categories including but not limited to cardiovascular, diabetes, urinary and central nervous system. With sales in more than 40 countries, Alvion licenses its products to the leading pharmaceutical companies across the world delivering an exceptional track record.

About V-Ensure

Established in 2010, V-Ensure Pharma technologies fully integrated specialty pharma company with more than a decade of experience in development of complex generics formulations for North America, EU, Australia and China. It has proprietary technology platforms and an established R&D track record with successful delivery of over 150 formulations including multiple 505 (b)(2), FTF and FTM opportunities. It has a fully equipped formulation & API R&D center and state of art solid oral manufacturing Facility which is audited by USFDA & EUGMP. 

For more information, please visit www.alvionpharma.com or contact us at bd@alvionpharma.com